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OBJECTIVE — We studied the C-peptide response to oral glucose with progression to type
1 diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) participants.
RESEARCH DESIGN AND METHODS — Among 504 DPT-1 participants 15 years
of age, longitudinal analyses were performed in 36 progressors and 80 nonprogressors. Progres-
sors had oral glucose tolerance tests (OGTTs) at baseline and every 6 months from 2.0 to 0.5
years before diagnosis; nonprogressors had OGTTs over similar intervals before their last visit.
Sixty-six progressors and 192 nonprogressors were also studied proximal to and at diagnosis.
RESULTS — The 30–0 min C-peptide difference from OGTTs performed 2.0 years before
diagnosis in progressors was lower than the 30–0 min C-peptide difference from OGTTs per-
formed2.0yearsbeforethelastvisitinnonprogressors(P0.01)andremainedlowerovertime.
The 90–60 min C-peptide difference was positive at every OGTT before diagnosis in progres-
sors, whereas it was negative at every OGTT before the last visit in nonprogressors (P  0.01 at
2.0years).ThepercentagewhosepeakC-peptideoccurredat120minwashigherinprogressors
at 2.0 years (P  0.05); this persisted over time (P  0.001 at 0.5 years). However, the peak
C-peptide levels were only signiﬁcantly lower at 0.5 years in progressors (P  0.01). The timing
of the peak C-peptide predicted type 1 diabetes (P  0.001); peak C-peptide levels were less
predictive (P  0.05).
CONCLUSIONS — A decreased early C-peptide response to oral glucose and an increased
later response occur at least 2 years before the diagnosis of type 1 diabetes.
Diabetes Care 33:620–625, 2010
S
tudies indicate that type 1 diabetes
develops over a period of years (1–5).
Immunologic damage and destruc-
tion of -cells result in ongoing metabolic
deteriorationthatcontinuesevenafterdiag-
nosis. It appears that there can be an in-
crease in glucose levels for at least 2 years
before diagnosis. This increase is rather
gradualinitially,butbecomesmorerapidas
onset approaches. Despite the increase in
glucose with progression, overall measures
of C-peptide from oral glucose tolerance
testing (OGTT), such as the area under the
curve (AUC) C-peptide, and the peak C-
peptide,changerelativelylittleuntilcloseto
diagnosis (2,6).
It is quite possible, however, that
overall measures of C-peptide fail to dis-
cern more subtle changes that occur with
progression to type 1 diabetes. The parti-
tioning of C-peptide responses according
to the time after an oral glucose challenge
could yield a better understanding of
changes in insulin secretion over time.
Thus, we have used the serial OGTTs
from the Diabetes Prevention Trial–Type
1 (DPT-1) (7,8) to examine changes in
earlierandlaterC-peptideresponsestoan
oralglucosechallengewithprogressionto
type 1 diabetes.
RESEARCH DESIGN AND
METHODS— There were 504 partic-
ipants of the parenteral and oral insulin
DPT-1 trials included in the analysis. For
certain analyses, subgroups of that cohort
were studied according to speciﬁc crite-
ria. All DPT-1 participants were islet cell
autoantibody (ICA)-positive relatives of
type 1 diabetic patients. Estimated 5-year
risks of 50 and 26–50% were required
for entry into the parenteral and oral in-
sulin trials, respectively. A 50% 5-year
risk estimate was based on a ﬁrst-phase
insulinresponsefromanintravenousglu-
cose tolerance test below a deﬁned
threshold and/or the presence of an
OGTTabnormalityotherthandiabetes.If
those metabolic criteria were not present,
but there were insulin autoantibodies, in-
dividuals were characterized as having a
26–50%5-yearrisk.Therewasnooverall
effect from the intervention in either trial.
Procedures
The interventions for the parenteral and
oral insulin trials were recombinant hu-
man ultralente insulin and recombinant
human insulin crystals, respectively.
OGTTs were performed at 6-month (3
month) intervals. For each OGTT, fasting
samples were obtained before oral glu-
cose administration (1.75 g/kg; maxi-
mum 75 g carbohydrate) and then at 30,
60, 90, and 120 min. If OGTTs were in
the diabetic range, participants were
asked to return for conﬁrmation with an-
other OGTT (unless contraindicated).
The procedure for the intravenous glu-
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elsewhere.
Laboratory measures
Methodologiesforassessingautoantibody
positivity in DPT-1 have been described
(9). These included measurements of
ICAs by indirect immunoﬂuorescence
and insulin autoantibodies by competi-
tive ﬂuid-phase radioassay. Plasma glu-
cosewasmeasuredbytheglucoseoxidase
method.InsulinandC-peptideweremea-
sured by radioimmunoassay. The interas-
say coefﬁcient of variation for the
C-peptide assay was 6.9% in a reference
pool with relatively high values and 7.8%
inareferencepoolwithrelativelylowval-
ues. Fasting C-peptide values in the un-
detectable range (0.2 ng/ml) were
assigned a value of 0.1 ng/ml for the
analyses.
Data analysis
For group and paired comparisons, t tests
and 
2 tests were used. Spearman corre-
lation was used to assess association. Cox
proportional hazards regression was used
for assessing type 1 diabetes associations
over time. Glucose tolerance abnormali-
ties were deﬁned as follows: impaired
fasting glucose  fasting glucose value
100–125 mg/dl; indeterminate  30-,
60-, and/or 90-min glucose value 200
mg/dl; and impaired glucose tolerance 
2-h glucose value 140–199 mg/dl. The
thresholds for diabetes were a fasting glu-
cose value 126 mg/dl and/or a 2-h glu-
cose value 200 mg/dl. The sum of
C-peptide levels after 30 min was calcu-
Figure 1—A: Glucose curves from OGTTs at baseline and 2.0 and 0.5 years before diagnosis in the progressors, and at baseline and corresponding
times before the last visit in the nonprogressors. In both the progressors and nonprogressors, glucose levels increased substantially at all OGTT time
points (AUC glucose: P  0.001 from baseline to 0.5 years in both groups). (Mean values are shown for the times before diagnosis or the last visit.)
B:C-peptidecurvesfromOGTTsatbaselineand2.0and0.5yearsbeforediagnosisintheprogressors,andatbaselineandcorrespondingtimesbefore
the last visit in the nonprogressors. In the nonprogressors, C-peptide levels increased at all OGTT time points (AUC C-peptide: P  0.001 from
baseline to 0.5 years). In the progressors, although the fasting and 120-min C-peptide levels were higher at 0.5 years than at baseline, there was no
signiﬁcant overall change (AUC C-peptide: P  0.936 from baseline to 0.5 years). (Mean values are shown for the times before diagnosis or the last
visit.)
Sosenko and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 621lated by subtracting the 30-min values
from the 60-, 90-, and 120-min values
and adding the sum of each of the differ-
ences. Theﬁrst-phase insulin response was
deﬁnedasthesumofinsulinlevelsatthe1st
and 3rd min of the intravenous glucose tol-
erancetest.Thetrapezoidalrulewasusedto
calculate OGTT AUC. The SAS 9.1.3 ver-
sion was used for the analyses. All P values
are two-sided.
RESULTS— A total of 504 DPT-1 par-
ticipants 15 years of age were included
in the overall study cohort (n  504;
9.2  3.1 years; 59% male). Of these in-
dividuals, data were analyzed for sequen-
tial glucose and C-peptide levels in 36
(9.0  3.1 years; 58% male) who pro-
gressed to type 1 diabetes (progressors)
and 80 (9.0  3.3 years; 65% male) who
did not progress to type 1 diabetes (non-
progressors). The progressors had
OGTTs performed every 6  3 months
for at least 2 years before diagnosis,
whereas the nonprogressors had OGTTs
performedevery63monthsforatleast
2 years before the last visit. The progres-
sors and nonprogressors all had normal
glucose tolerance at baseline.
Glucose and C-peptide curves from
OGTTs performed at baseline and at 2.0
and 0.5 years before diagnosis in the pro-
gressors, or at baseline and at 2.0 and 0.5
years before the last visit in the nonpro-
gressors,areshowninFig.1.Glucoselev-
els (Fig. 1A) increased signiﬁcantly from
baseline to 0.5 years at all OGTT time
points in both the progressors and non-
progressors, but to a greater extent in the
progressors. The increase in the AUC glu-
cosefrombaselineto0.5yearswashighly
signiﬁcant for both (P  0.001).
C-peptide levels (Fig. 1B) increased
signiﬁcantly at each OGTT time point
from baseline to 0.5 years in the nonpro-
gressors (P  0.001 for the AUC C-
peptide from baseline to 0.5 years).
However, the change in C-peptide levels
Figure 2—A: The difference (mean  SE) in C-peptide levels from 0 to 30 min (the 30–0 min C-peptide difference) according to the times before
diagnosis (progressors) or the times before the last visit (nonprogressors). The 30–0 min C-peptide difference was consistently lower in the
progressors than in the nonprogressors. (Mean values are shown for the times before diagnosis or the last visit.) B: The difference (mean  SE) in
C-peptide levels from 60 to 90 min (the 90–60 min C-peptide difference) according to the times before diagnosis (progressors) or the times before
the last visit (nonprogressors). At every time before diagnosis, the 90–60 min C-peptide difference was positive in the progressors, whereas at every
time before the last visit, it was negative in the nonprogressors. (Mean values are shown for the times before diagnosis or the last visit.)
Glucose and C-peptide with progression to type 1 diabetes
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sors varied according to the OGTT time
point. Fasting and 120-min C-peptide
levelsincreasedfrombaselineto0.5years
(P  0.01 and P  0.05, respectively) in
the progressors, but there was no signiﬁ-
cant change at the other OGTT time
points nor in the AUC C-peptide (P 
0.936).
We compared the 30–0 min C-
peptide difference at baseline and every 6
months for 2 years before diagnosis in the
progressorswiththe30–0minC-peptide
difference at baseline and at correspond-
ing times before the last visit in the non-
progressors.(Amongthe504participants
at baseline, there was a positive correla-
tion between the 30–0 min C-peptide
difference and the ﬁrst-phase insulin re-
sponse [r  0.50, P  0.001]). The 30–0
min C-peptide difference (Fig. 2A) was
similar at baseline; however, by 2.0 years,
that difference was lower in the progres-
sors (P  0.01). Among the progressors,
the 30–0 min C-peptide difference de-
clined from baseline to 0.5 years before
diagnosis (P  0.01).
Whereas the 90–60 min C-peptide
difference (Fig. 2B) was negative (i.e., the
90-min value was less than the 60-min
value) at all times before the last visit in
the nonprogressors, it was positive at all
times before diagnosis in the progressors.
This contrast was not only signiﬁcant at
2.0 (P  0.01), 1.0 (P  0.01), and 0.5
years (P  0.001), but also at baseline
(P  0.05).
As an overall measure of later C-
peptide responsiveness to oral glucose,
we used the sum of each of the C-peptide
differences of the 30-min value sub-
tracted from the values at 60, 90, and 120
min (C-peptide sum after 30 min). Figure
3 shows that those values were signiﬁ-
cantly higher in the progressors than in
thenonprogressorsatcorrespondingtime
points from 2.0 years to 1.0 year. Values
were also higher, but not signiﬁcantly so,
at baseline and at 0.5 years. Among the
progressors, the C-peptide sum after 30
min increased signiﬁcantly from baseline
to all subsequent time points (P  0.05
from baseline to 2.0 years and to 0.5
years; P  0.01 from baseline to 1.5 years
and to 1.0 year).
Consistent with the above ﬁndings,
the timing of the peak C-peptide was de-
layed in the progressors. The percentage
of individuals with the peak C-peptide
occurring at 120 min was signiﬁcantly
higher in the progressors at 2.0 years (39
vs.21%,P0.05).By0.5years,thepeak
C-peptide occurred at 120 min in 56% of
the progressors compared with 18% of
the nonprogressors (P  0.001). Actual
peak C-peptide levels did not differ be-
tween the progressors and nonprogres-
sorsuntil0.5years(P0.01).Amongthe
full cohort of 504 at baseline, the occur-
rence of the peak C-peptide at 120 min
and the 90–60 min C-peptide difference
(above versus below 0) were both highly
predictive of type 1 diabetes with and
without age as a covariate (P  0.001) in
proportionalhazardsmodels;thepeakC-
peptide level was somewhat predictive
(P0.028), but not with age in the model.
Figure 4 shows C-peptide changes in
theprogressorswhohadOGTTs0.5years
before diagnosis and at diagnosis (n  66),
and in the nonprogressors who had
OGTTs 0.5 years before the last visit and
at the last visit (n  192). The 30–0 min
C-peptide difference (Fig. 4A) declined
considerably in the progressors (P 
0.001). The C-peptide sum after 30 min
declinedsomewhatatdiagnosis,butnot
below levels in the nonprogressors at
thelastvisit(Fig.4B).Evenatdiagnosis,
the delay in the peak C-peptide per-
sisted. The peak C-peptide occurred at
120 min in 52% of the progressors at
diagnosis compared with 23% of the
nonprogressors at their last visit (P 
0.001).
CONCLUSIONS — The data suggest
that the early C-peptide response to oral
glucose can be decreased for at least 2
yearsbeforethediagnosisoftype1diabe-
tes and especially as diagnosis ap-
proaches. Although the early C-peptide
response to the glucose challenge de-
clines, C-peptide levels increase at later
time points. This was evident in the inter-
val from 60 to 90 min. The C-peptide in-
crease in that interval in the progressors
contrasted with the decline in the non-
progressors.Itappearsthattheincreasein
C-peptide levels from 60 to 90 min can
occur even 3 years before diagnosis. This
prolonged increase in C-peptide levels af-
ter the glucose challenge is also mani-
festedbyadelayedpeakC-peptideatleast
2 years before diagnosis.
It is possible that the continuing in-
crease in C-peptide levels after 30 min in
progressors occurs as a result of the deﬁ-
cient early C-peptide response. However,
the later C-peptide response still does not
prevent glucose levels from rising, as is
evident in Fig. 1. The decrease in the C-
peptide sum after 30 min at diagnosis
Figure 3—The C-peptide sum after 30 min (mean  SE) according to the times before diagnosis (progressors) or the times before the last visit
(nonprogressors).Thevalueswerehigherintheprogressorsfrombaselineto0.5years.(Meanvaluesareshownforthetimesbeforediagnosisorthe
last visit.)
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ing by that time.
There are few longitudinal data avail-
able regarding the metabolic progression to
type 1 diabetes. Although we have previ-
ously examined changes in C-peptide and
glucose indexes with progression to type 1
diabetes(4),datapertainingtothetimingof
theC-peptideresponsebeforethediagnosis
of type 1 diabetes has not been reported,
nor has the prediction of type 1 diabetes by
the timing of the C-peptide response been
reported. A decreased early insulin re-
sponse was a risk factor for progression to
type 2 diabetes in Pima Indians. However,
in contrast to our ﬁndings for type 1 diabe-
tes,adecreased(ratherthanincreased)later
insulin response was predictive of type 2
diabetesinPimaIndianswithimpairedglu-
cose tolerance (10).
The decreased early C-peptide re-
sponse together with the increased later
C-peptide response to oral glucose that
we observed in the “pre-diabetic” state of
type 1 diabetes is similar to the abnormal
insulin responses to oral glucose in pa-
tients already diagnosed with type 2 dia-
betes (11,12). This suggests that there
could be some commonality between the
disorders in the progression of metabolic
abnormalities.
The analysis was limited to children,
since the nonprogressors were apprecia-
bly older than the progressors in the full
DPT-1 cohort. By restricting the analysis
to younger individuals, differences in
progressionduetoanageeffectweremin-
imized. Also, among individuals who de-
veloped type 1 diabetes, pathogenetic
heterogeneity related to age was lessened.
The numbers were insufﬁcient to speciﬁ-
cally examine the older age-group.
Figure 4—A: The 30–0 min C-peptide difference (mean  SE) in the progressors who had OGTTs 0.5 years before diagnosis and at diagnosis and
in the nonprogressors who had OGTTs 0.5 years before the last visit and at the last visit. The 30–0 min C-peptide difference declined considerably
in the progressors. B: The C-peptide sum after 30 min (mean  SE) in the progressors who had OGTTs 0.5 years before diagnosis and at diagnosis
and in the nonprogressors who had OGTTs 0.5 years before the last visit and at the last visit. The C-peptide sum after 30 min declined, but did not
fall below that in the nonprogressors.
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624 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgBecause a number of the nonprogres-
sors would probably ultimately develop
type 1 diabetes, and thus were not meta-
bolically normal, differences between
progressorsandanormalreferencegroup
could be even more substantial. It is of
interest that there was such a marked in-
crement in C-peptide over time in the
nonprogressors. This could represent
typicalchangeswithaging,earlypathoge-
netic changes, or both. The pattern of
change suggests increasing insulin resis-
tance over time.
The ﬁndings in this report help to ex-
plain why such measures as peak C-
peptide and AUC C-peptide values
provide relatively little information with
regardtothepredictionoftype1diabetes
and to its natural history. Those indexes
changelittlewithprogressionbecausethe
deﬁcient early C-peptide response to the
oral glucose challenge is somewhat bal-
anced by a continuing compensatory re-
sponse until close to diagnosis. Thus, the
peak C-peptide and AUC C-peptide in-
dexesfailtodetectthesubstantialchanges
in the -cells that are occurring years be-
fore diagnosis. It is evident that OGTTs
can yield appreciably more prediction
and natural history information when
they are partitioned according to the time
after the glucose challenge.
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